Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens

Oncogene

Volumn 31, Issue 43, 2012, Pages 4588-4598

  Dart, D A ^a   Brooke, G N ^a   Sita Lumsden, A ^a   Waxman, J ^b   Bevan, C L ^a  

^a Department of Surgery and Cancer   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

androgen receptor; androgens; castrate resistant prostate cancer; corepressor; prohibitin; prostate

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIONE; COMPLEMENTARY DNA; PROHIBITIN; TRANSCRIPTION FACTOR;

ANDROGEN THERAPY; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR OCCUPANCY; TUMOR GROWTH;

ACETYLATION; ADRENAL GLANDS; ANDROGENS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS;

EID: 84867899882     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.591     Document Type: Article

References (41)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Kokontis JM, Liao S. Molecular action of androgen in the normal and neoplastic prostate. Vitam Horm 1999; 55: 219-307.
3. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26: 407-421. (Pubitemid 29411449)
4. Tsai M-J, O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-486. (Pubitemid 24218640)
5. Brinkmann AO, Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000; 6: 628-629. (Pubitemid 30398780)
6. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004; 10: 26-27. (Pubitemid 38524693)
7. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10: 18-25.
8. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.
9. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-486. (Pubitemid 24218640)
10. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol 2001; 179: 105-109. (Pubitemid 32564957)
11. Brinkmann AO, Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000; 6: 628-629. (Pubitemid 30398780)
12. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004; 10: 26-27. (Pubitemid 38524693)
13. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 2007; 26: 1757-1768. (Pubitemid 46426196)
14. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004; 23: 2996-3004. (Pubitemid 38648190)
15. Nijtmans LG, Artal SM, Grivell LA, Coates PJ. The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci 2002; 59: 143-155. (Pubitemid 34117362)
16. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005; 7: 837-843. (Pubitemid 41079057)
17. Coates PJ, Jamieson DJ, Smart K, Prescott AR, Hall PA. The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr Biol 1997; 7: 607-610.
18. McClung JK, Jupe ER, Liu XT, Dell'Orco RT. Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 1995; 30: 99-124.
19. Choi D, Lee SJ, Hong S, Kim IH, Kang S. Prohibitin interacts with RNF2 and regulates E2F1 function via dual pathways. Oncogene 2008; 27: 1716-1725. (Pubitemid 351380260)
20. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002; 21: 8388-8396. (Pubitemid 36054881)
21. He B, Feng Q, Mukherjee A, Lonard DM, DeMayo FJ, Katzenellenbogen BS et al. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol 2008; 22: 344-360. (Pubitemid 351185935)
22. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003; 278: 47853-47861. (Pubitemid 37523233)
23. Wang S, Zhang B, Faller DV. BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. Embo J 2004; 23: 2293-2303. (Pubitemid 38833238)
24. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008; 29: 1725-1733.
25. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 2006; 26: 4161-4171. (Pubitemid 43788018)
26. Eissenberg JC, Elgin SC. The HP1 protein family: getting a grip on chromatin. Curr Opin Genet Dev 2000; 10: 204-210. (Pubitemid 30182255)
27. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer 2009; 16: 1157-1169.
28. Pignatelli D, Xiao F, Gouveia AM, Ferreira JG, Vinson GP. Adrenarche in the rat. J Endocrinol 2006; 191: 301-308. (Pubitemid 44756531)
29. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992; 50: 857-861.
30. de la Torre B, Benagiano G, Diczfalusy E. Pathways of testosterone synthesis in decapsulated testes of mice. Acta Endocrinologica 1976; 81: 170-184.
31. Feek CM, Tuzi NL, Edwards CR. The adrenal gland and progesterone stimulates testicular steroidogenesis in the rat in vivo. J Steroid Biochem 1989; 32: 573-579. (Pubitemid 19135508)
32. Mullins LJ, Peter A, Wrobel N, McNeilly JR, McNeilly AS, Al-Dujaili EA et al. Cyp11b1 null mouse, a model of congenital adrenal hyperplasia. J Biol Chem 2009; 284: 3925-3934.
33. Min W, Pober JS, Johnson DR. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J Immunol 1996; 156: 3174-3183. (Pubitemid 26123530)
34. Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E et al. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J 2007; 401: 155-166. (Pubitemid 46114609)
35. Kang Z, Pirskanen A, Janne OA, Palvimo JJ. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 2002; 277: 48366-48371. (Pubitemid 35470792)
36. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004; 18: 2633-2648. (Pubitemid 39482054)
37. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M et al. Estrogen receptoralpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115: 751-763. (Pubitemid 38030303)
38. Shi SL, Li QF, Liu QR, Xu DH, Tang J, Liang Y et al. Nuclear matrix protein, prohibitin, was down-regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). J Cell Biochem 2009; 108: 926-934.
39. Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C et al. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta, 17beta-diol. J Steroid Biochem Mol Biol 2004; 91: 247-257. (Pubitemid 39172133)
40. Jia L, Coetzee GA. Androgen receptor-dependent PSA expression in androgenindependent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res 2005; 65: 8003-8008. (Pubitemid 41297280)
41. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003; 63: 4552-4560. (Pubitemid 36951029)